Successful sulfonylurea treatment of a neonate with neonatal diabetes mellitus due to a new KCNJ11 mutation

Miloš M Ješić; Maja D Ješić; Svjetlana Maglajlić; Silvija Sajić; Svetislav Necić

doi:10.1016/j.diabres.2010.09.027

Successful sulfonylurea treatment of a neonate with neonatal diabetes mellitus due to a new KCNJ11 mutation

Diabetes Res Clin Pract. 2011 Jan;91(1):e1-3. doi: 10.1016/j.diabres.2010.09.027. Epub 2010 Nov 5.

Authors

Miloš M Ješić¹, Maja D Ješić, Svjetlana Maglajlić, Silvija Sajić, Svetislav Necić

Affiliation

¹ Department of Neonatology, University Children's Hospital, Tiršova 10, Belgrade, Serbia. milos.jesic@udk.bg.ac.rs

PMID: 21056492
DOI: 10.1016/j.diabres.2010.09.027

Abstract

Mutations in the KCNJ11 gene, which encodes the Kir6.2 subunit of the ATP-sensitive potassium channel, often result in neonatal diabetes. We describe a female neonate who is a heterozygous for a new missense mutation, V252L, in the KCNJ11 gene and who has been successfully transitioned from insulin to sulfonylurea therapy.

Publication types

Case Reports

MeSH terms

Diabetes Mellitus / drug therapy*
Diabetes Mellitus / genetics*
Female
Glyburide / adverse effects
Glyburide / therapeutic use
Heterozygote
Humans
Hypoglycemic Agents / adverse effects
Hypoglycemic Agents / therapeutic use*
Infant, Newborn
Mutation, Missense*
Potassium Channels, Inwardly Rectifying / chemistry
Potassium Channels, Inwardly Rectifying / genetics*
Sulfonylurea Compounds / adverse effects
Sulfonylurea Compounds / therapeutic use*
Treatment Outcome

Substances

Hypoglycemic Agents
Kir6.2 channel
Potassium Channels, Inwardly Rectifying
Sulfonylurea Compounds
Glyburide